Skip to content
sellWeak cluster of 210b5-1 plan

Dinesh Ph D Patel V sold $7.5M of PTGX

President and CEO at Protagonist Therapeutics, Inc. 75,000 shares at an average of $100.12, traded May 12, 2026, filed May 14, 2026.

Warning score
28
Value
$7.5M
75,000 shares
Holdings after
523,478
-13% from before
From 52-week low
+128%
low $43.77, close $99.95
From 52-week high
-6%
high $105.98, as of May 12, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $7.5M at market
    +25
  • Share of holdings sold
    Sold 13% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PTGXOct 9, 2026 · close 143.73
Since filing May 14, 2026: +36.2%SPY +4.6% · excess +31.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-26-061476, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 12, 2026MOption exercise
Common Stock10b5-1
+75,000$21.58$1.6M598,478May 14, 2026
May 12, 2026SOpen-market sale
Common Stock10b5-1
-75,000$100.12$7.5M523,478May 14, 2026
May 12, 2026MOption exercise
Stock Option (right to buy)derivative10b5-1
-75,000$0.00$0225,000May 14, 2026

Related signals

Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
22Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$8.3M
58,629 shares
-50%
20Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$18M
125,000 shares
-22%
20Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$15M
100,000 shares
-17%
25Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$1.1M
9,000 shares
-53%
25Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$969k
9,000 shares
-53%
24Weak
PTGXsell10b5-1
Protagonist Therapeutics, Inc
William D. Waddill
director
$897k
9,000 shares
-53%
48Moderate
PTGXsell 2
Protagonist Therapeutics, Inc
Dinesh Ph D Patel V
President and CEO
$7.5M
75,000 shares
-13%
53Moderate
PTGXsell 2
Protagonist Therapeutics, Inc
Bryan Giraudo
director
$5.9M
59,130 shares
-93%
34Weak
PTGXsell
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$185k
1,750 shares
-3%
57Moderate
PTGXsell 4
Protagonist Therapeutics, Inc
Asif Ali
Chief Financial Officer
$2.6M
24,765 shares
-29%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Dinesh Ph D Patel V sold $7.5M of PTGX | InsiderTell